Equities analysts expect Zimmer Biomet Holdings Inc (NYSE:ZBH) to post sales of $2.03 billion for the current fiscal quarter, Zacks Investment Research reports. Eleven analysts have issued estimates for Zimmer Biomet’s earnings, with estimates ranging from $2.01 billion to $2.04 billion. Zimmer Biomet reported sales of $2.01 billion in the same quarter last year, which would suggest a positive year over year growth rate of 1%. The company is scheduled to report its next earnings report on Tuesday, January 30th.

According to Zacks, analysts expect that Zimmer Biomet will report full year sales of $2.03 billion for the current year, with estimates ranging from $7.76 billion to $7.83 billion. For the next year, analysts expect that the business will post sales of $7.92 billion per share, with estimates ranging from $7.79 billion to $8.04 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Zimmer Biomet.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The company had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. During the same quarter in the prior year, the company posted $1.79 earnings per share. The business’s revenue was down .8% compared to the same quarter last year.

Several equities analysts have recently commented on ZBH shares. Deutsche Bank upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price objective on the stock in a report on Tuesday, November 14th. Zacks Investment Research downgraded shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research note on Monday, November 20th. Edward Jones raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Thursday, November 9th. TheStreet downgraded shares of Zimmer Biomet from a “b-” rating to a “c+” rating in a research note on Friday, November 24th. Finally, SunTrust Banks set a $136.00 target price on shares of Zimmer Biomet and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. Zimmer Biomet has a consensus rating of “Hold” and an average target price of $134.05.

Several large investors have recently made changes to their positions in the business. BlackRock Inc. increased its position in shares of Zimmer Biomet by 4.1% in the 2nd quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock valued at $2,236,657,000 after purchasing an additional 679,080 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Zimmer Biomet by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 13,380,517 shares of the medical equipment provider’s stock valued at $1,718,057,000 after purchasing an additional 339,106 shares during the last quarter. Longview Partners Guernsey LTD increased its position in shares of Zimmer Biomet by 17.7% in the 3rd quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock valued at $878,958,000 after purchasing an additional 1,128,973 shares during the last quarter. Nordea Investment Management AB increased its position in shares of Zimmer Biomet by 7.3% in the 3rd quarter. Nordea Investment Management AB now owns 5,277,660 shares of the medical equipment provider’s stock valued at $617,961,000 after purchasing an additional 357,302 shares during the last quarter. Finally, Jana Partners LLC increased its position in shares of Zimmer Biomet by 16.6% in the 3rd quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock valued at $545,932,000 after purchasing an additional 662,497 shares during the last quarter. 86.24% of the stock is currently owned by institutional investors.

Shares of Zimmer Biomet (ZBH) traded down $0.70 during mid-day trading on Thursday, hitting $112.82. 1,289,909 shares of the stock traded hands, compared to its average volume of 1,362,183. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47. Zimmer Biomet has a 52-week low of $100.81 and a 52-week high of $133.49. The firm has a market cap of $22,900.00, a price-to-earnings ratio of 14.07, a P/E/G ratio of 1.76 and a beta of 1.15.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/14/2-03-billion-in-sales-expected-for-zimmer-biomet-holdings-inc-zbh-this-quarter-2.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Get a free copy of the Zacks research report on Zimmer Biomet (ZBH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.